Hot Topics

Poll

Why is it a big mistake to link funding of R&D costs with drug prices?:

Opening statement of Uruguay at WIPO's 22nd Standing Committee on Copyright and Related Rights

Comité Permanente de Derechos de Autor y Conexos – SCCR 22 – OMPI - Ginebra
Intervención de la Delegación de Uruguay. Ginebra, 15 de junio de 2011.

Gracias Señor Presidente,

Señor Presidente, reciba de nuestra delegación nuestras mas sinceras felicitaciones por su designación como Presidente del Comité Permanente de Derechos de Autor y Conexos SCCR y cuente con nuestro apoyo para hacer una exitosa gestión al frente de este importante comité.

Señor Presidente:

Pharmaceutical global R&D was 7.9 percent of sales in 2010

Using industry assertions of R&D spending, pharmaceutical related R&D spending by the private sector was less than 8 percent of global sales in 2010.


sales_rnd_2010_0.png
These are the data:

2010 Global R&D by all private companies: - $67.4 billion
Source: Page 2 of the 2011 PhRMA industry profile
http://report.nih.gov/investigators_and_trainees/acd_bwf/pdf/Phrma_Indus...

2010 Global sales - $856 billion

KEI Intervention at UN HLM on HIV: De-Linking R&D costs from drug prices and the sustainability of treatment

un_hlm_panel_3_IMG_2446.JPGThese are the notes from my intervention today at the UN's High Level Meeting on HIV/AIDS in New York. The persons making statements from the floor were asked to keep their comments to two minutes, so the actual intervention was somewhat shorter. Jamie

2011 High-Level Meeting on
the comprehensive review of the progress achieved in realizing
the Declaration of Commitment on HIV/AIDS and

WHO Executive Board Decision 129(8): WHO reform for a healthy future

On Wednesday, 25 May 2011, the 129th session of the World Health Organization's Executive Board approved Decision, EB129(8) on "WHO reform for a healthy future". Reproduced below is the text of the Decision which is yet to be published on the WHO website in all 6 UN languages.

EB129(8) WHO reform for a healthy future

The Executive Board,

Karl De Gucht writes Andris Piebalgs on topic of European Union IPR demands on India and other developing countries

KEI has received a copy of a May 16, 2011 letter from Karl De Gucht to Andris Piebalgs, which discusses (1) the EU-India FTA, and (2) Relations between IPR and development policies.

Senator Sanders introduces two medical innovation prize bills in U.S. Senate to de-link R&D costs from drug prices

Sanders_IMG_3442.jpgOn Thursday, May 26, 2011, Senator Bernie Sanders (I-VT) introduced two bills in the United States Senate that would de-link R&D costs from drug prices. The bill names and numbers are as follows:

  • The Medical Innovation Prize Fund Act: S. 1137
  • The Prize Fund for HIV/AIDS Act: S. 1138

KEI Technical Meeting to Discuss Innovation Inducement Prizes, June 3, 2011

There is a growing interest in the use of innovation inducement prizes to stimulate investments in medical research and development.

  • The Obama Administration and the European Commission are exploring the role of innovation inducement prizes.
  • On May 31, 2011, the European Parliament is holding one of several meetings on innovation inducement prizes for medical technologies.

Draft WHO Executive Board resolution on WHO reform

At 18:30 Geneva time on 25 May 2011, during the 129th session of the WHO Executive Board, the EB is considering the following draft decision on WHO reform.

Chair's text, based on draft proposed by Ecuador

The 29th [sic] Executive Board,

(OP.1) DECIDES to establish an incremental, transparent, Member-State driven and inclusive consultative process comprising of the following elements:

Letter to the 129th WHO Executive Board on conflicts of interest, WHO reform and the future of financing

24 May 2011

NGO letter on Conflicts of Interest, Future Financing, Reform and governance of the WHO.

Dear Members of the Executive Board,

SCP 16: Summary by the Chair


WIPO
World Intellectual Property Organization

SCP/16/8 PROV.
ORIGINAL: ENGLISH
DATE: MAY 20, 2011

Standing Committee on the Law of Patents

Sixteenth Session
Geneva, May 16 to 20, 2011

SUMMARY BY THE CHAIR

Agenda Item 1: Opening of the session

1. The sixteenth of the Standing Committee on the Law of Patents (SCP) was opened by Mr. James Pooley, Deputy Director General, who welcomed the participants. Mr. Philippe Baechtold (WIPO) acted as Secretary.

BRICS Health Ministers’ preparatory meeting – May 17th 2011

BRICS Health Ministers’ preparatory meeting – May 17th 2011
Press release

Consistent with the mandate of the Sanya Declaration of the BRICS Leaders Meeting (14 April 2011), the Ministers of Health of the five BRICS’ countries met on the sidelines of the 64thWorld Health Assembly, on 17 May 2011, to discuss issues of common interest as well as prepare the BRICS Health Ministerial Meeting to be held in Beijing, China, on 11 July 2011. Representatives of WHO and UNAIDS also attended the meeting.

SCP16: KEI intervention on Patents and Health

16th session of the WIPO Standing Committee of the Law of Patents (SCP)
Thursady, 19 May 2011

KEI Statement on Patents and Health

KEI is impressed by and fully supportive of the joint proposal of the African Group and the Development Agenda Group on a work program on Patents and Health, which has been published as SCP/16/7. We agree with the comments of the Chair that the proposal is both comprehensive and well thought out.

Syndicate content